Head-to-head · Cost-Efficiency Index
He & She MD vs SkinnyRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
He & She MD
Shoppers comparing injectable semaglutide specifically, where the advertised $199 genuinely is the standing price — not oral semaglutide or tirzepatide, which roll higher after 6 months.
Visit He & She MDSkinnyRx
Shoppers who have already decided on a long commitment and want the term priced openly rather than hidden behind an intake — not price-first shoppers comparing on the advertised figure.
Visit SkinnyRxThe verdict
He & She MD and SkinnyRx tie on the Cost-Efficiency Index at 71/100, so neither wins outright on the numbers. For most shoppers we'd start with He & She MD (ranked #59, a hair above #60) — Shoppers comparing injectable semaglutide specifically, where the advertised $199 genuinely is the standing price — not oral semaglutide or tirzepatide, which roll higher after 6 months. But SkinnyRx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs He & She MD.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | He & She MD | SkinnyRx |
|---|---|---|
| Cost-Efficiency Index | 71/100 | 71/100 |
| Semaglutide / mo | $199/mo (month to month, compounded; every lower rate is a prepaid term) | $349/mo month-to-month ($299 on 4 months, $249 on 6, $199 only on 12) |
| Tirzepatide / mo | $299/mo (month to month, compounded; every lower rate is a prepaid term) | $399/mo month-to-month ($349 on 4 months, $329 on 6, $299 only on 12) |
| Semaglutide / yr (modeled) | $2,388 | $4,188 |
| Tirzepatide / yr (modeled) | $2,388 | $4,788 |
| Coverage | All states except Louisiana (GLP-1) | Most states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #59 | #60 |
He & She MD
71/100Where the value is
- Compounded semaglutide and tirzepatide (injectable or oral), with brand-name access to Ozempic, Wegovy, and Zepbound also offered
- Named pharmacy (F&F Pharmacies Inc DBA Jungle Jim's Pharmacy, Fairfield OH) and named CMO (Dr. Ozita Cooper, MD)
- Free expedited shipping and unlimited board-certified clinician access
The tradeoffs
- Its own FAQ says the pharmacy it names holds a license in 44 US states, none in California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia or Delaware, and “cannot dispense sterile compounds” — while the same FAQ says GLP-1s ship everywhere except Louisiana. Injectable GLP-1s are sterile compounds, and the site never says which of its two pharmacies covers the gap
- The uniform '$199 to start' banner across all three tracks obscures that only injectable semaglutide holds at $199 ongoing — oral semaglutide rolls to $239/mo and injectable tirzepatide rolls to $289/mo after the first 6-month cycle
SkinnyRx
71/100Where the value is
- A complete four-term ladder for both molecules is published rather than gated, so the cost of not committing is knowable before signup
- Both compounded molecules are offered, with the same term structure on each
- The twelve-month rate is genuinely low for the category if a year is a commitment you were going to make anyway
The tradeoffs
- The '$199/month' it advertises everywhere is the TWELVE-MONTH rung. The rate you can stop after a month is $349 — 75% higher — and the figure appears without that term attached
- An FDA warning letter is on public record against Lean Rx, Inc. dba SkinnyRx, issued 20 February 2026. We disclose it and we do not treat it as disqualifying
Regulatory note: the FDA issued a warning letter to Lean Rx, Inc. dba SkinnyRx in February 2026. We still list and link to SkinnyRx; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.